Oral Oncology

Viome Launches Clinically Validated Oral Health and Early Stage Cancer Detection Test For Dental Professionals

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Technology, Managed Care, Other Health, Health, Oncology, Other Technology, Infectious Diseases, Software, Artificial Intelligence, Dental, Nucleotide, Bad breath, Gene expression, Biomarker, New York Medical College, RNA, Trial of the century, Dentist, Oral Oncology, Patient, Griffith University, Dentistry, Machine learning, Data, Oral hygiene, Oral cancer, AI, FDA, Otorhinolaryngology, Mouth, Saliva, Pharmaceutical industry

This groundbreaking test is set to revolutionize the industry’s approach to oral care by providing dental professionals with an unprecedented level of actionable insight into their patients' health.

Key Points: 
  • This groundbreaking test is set to revolutionize the industry’s approach to oral care by providing dental professionals with an unprecedented level of actionable insight into their patients' health.
  • “The Oral Health Pro test is ushering in a new era of preventative care that benefits patients and dental professionals.
  • Oral Health Pro is also changing the way dental professionals and individuals approach oral health, highlighting the profound link between the health of the mouth and the overall well-being of the body.
  • Oral Health Pro is a cloud-based, no-cost, software product with a frictionless workflow so can easily be integrated into any practice.

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

Retrieved on: 
Wednesday, March 1, 2023
Clinical trial, Tacrolimus, American Osteopathic Board of Ophthalmology and Otolaryngology, Coronavirus Scientific Advisory Board, DMD, Cone Health Women's Hospital, Associate, UCSF, MHS, Infection, Research, Immunity, Disease, IND, Oral medicine, Harvard School of Dental Medicine, DDS, FIU Herbert Wertheim College of Medicine, FDA, Tufts University School of Dental Medicine, Dentistry, Oral, Division, Hospital, Wake Forest School of Medicine, MPH, Oral Oncology, OLP, Oral and maxillofacial surgery, LIPO, Pharmaceutical industry, Vaccine, Doctor of Philosophy, Brigham

PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.  

Key Points: 
  • PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
  • The five-member Board will initially focus on the development of LP-310, Lipella's product candidate for the treatment of symptomatic oral lichen planus (OLP).
  • Members of the advisory board include:
    Alessandro Villa, DDS, PhD, MPH will serve as the inaugural Chair of the Scientific Advisory Board.
  • Dr. Villa is the Chief of Oral Medicine, Oral Oncology and Dentistry at Miami Cancer Institute and Professor, Herbert Wertheim College of Medicine, Miami, FL.

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Survival, ASCO, RECIST, NDA, Literature, Oral Oncology, Lung cancer, CEO, GLOBE, Neoplasm, Failure, Private Securities Litigation Reform Act, SOM, SEC, Cancer, Investment, AESOP, Incidence, Esophagitis, Annual report, NSCLC, Patient, Review, Therapy, COVID-19, LAPC, Chemoradiotherapy, Large-cell lung carcinoma, Pancreatic cancer, Society, Safety, U.S. FDA, Research, ISOO, SBRT, Privacy, Head, Ownership, GC4419, Wastewater treatment, Nasdaq, Food, Health, Pharmaceutical industry, Tutoring, Company

MALVERN, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

Key Points: 
  • An oral presentation on Phase 3 ROMAN data of avasopasem for SOM was given at the 2022 ASCO Annual Meeting.
  • Research and development expenses were $6.7 million in the second quarter of 2022, compared to $16.0 million for the same period in 2021.
  • General and administrative expenses were $5.3 million in the second quarter of 2022, broadly consistent with the second quarter of 2021.
  • As of June 30, 2022, Galera had cash, cash equivalents and short-term investments of $52.0 million.

Enzychem Lifesciences Announces Acceptance of EC-18 Abstract for Oral Proffered Paper at the MASCC/ISOO 2022 Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Head, KOSDAQ, University, Clinical trial, Wastewater treatment, Patient, Radiation therapy, Inflammation, Edwards Lifesciences, M.D, International Society, HNC, Oral Oncology, Homeostasis, Pharmaceutical industry, Medical imaging, Cancer

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.
  • The abstract highlights the new clinical data from Enzychems Phase 2 US clinical trial evaluating EC-18 in head and neck cancer (HNC) patients with chemoradiation-induced oral mucositis (CRIOM).
  • I am honored to present Enzychems clinical data at the MASCC/ISOO 2022 annual meeting, said Dr. Christina Henson.
  • Enzychem is headquartered in South Korea, with an office in the United States.